XML 85 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Statements of Income (USD $)
In Thousands, except Per Share data, unless otherwise specified
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Net revenue $ 724,408us-gaap_SalesRevenueNet $ 687,864us-gaap_SalesRevenueNet $ 558,588us-gaap_SalesRevenueNet
Operating expenses:      
Cost of revenue 287,630us-gaap_CostOfGoodsAndServicesSold 262,785us-gaap_CostOfGoodsAndServicesSold 177,339us-gaap_CostOfGoodsAndServicesSold
Research and development 159,181us-gaap_ResearchAndDevelopmentExpense 146,930us-gaap_ResearchAndDevelopmentExpense 126,423us-gaap_ResearchAndDevelopmentExpense
Selling, general and administrative 342,164us-gaap_SellingGeneralAndAdministrativeExpense 264,958us-gaap_SellingGeneralAndAdministrativeExpense 171,753us-gaap_SellingGeneralAndAdministrativeExpense
Total operating expenses 788,975us-gaap_CostsAndExpenses 674,673us-gaap_CostsAndExpenses 475,515us-gaap_CostsAndExpenses
(Loss) income from operations (64,567)us-gaap_OperatingIncomeLoss 13,191us-gaap_OperatingIncomeLoss 83,073us-gaap_OperatingIncomeLoss
Settlement 25,736us-gaap_GainLossRelatedToLitigationSettlement 0us-gaap_GainLossRelatedToLitigationSettlement 0us-gaap_GainLossRelatedToLitigationSettlement
Co-promotion and profit share income 24,236mdco_CoPomotionIncome 17,383mdco_CoPomotionIncome 10,000mdco_CoPomotionIncome
Loss in equity investment (1,711)us-gaap_IncomeLossFromEquityMethodInvestments 0us-gaap_IncomeLossFromEquityMethodInvestments 0us-gaap_IncomeLossFromEquityMethodInvestments
Interest expense (15,701)us-gaap_InterestExpense (15,531)us-gaap_InterestExpense (8,005)us-gaap_InterestExpense
Investment impairment (7,500)us-gaap_CostmethodInvestmentsOtherThanTemporaryImpairment 0us-gaap_CostmethodInvestmentsOtherThanTemporaryImpairment 0us-gaap_CostmethodInvestmentsOtherThanTemporaryImpairment
Other income 322us-gaap_OtherNonoperatingIncomeExpense 1,577us-gaap_OtherNonoperatingIncomeExpense 1,140us-gaap_OtherNonoperatingIncomeExpense
(Loss) income before income taxes (39,185)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments 16,620us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments 86,208us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Benefit (provision) for income taxes 6,837us-gaap_IncomeTaxExpenseBenefit (1,360)us-gaap_IncomeTaxExpenseBenefit (35,038)us-gaap_IncomeTaxExpenseBenefit
(Loss) net income (32,348)us-gaap_NetIncomeLoss 15,260us-gaap_NetIncomeLoss 51,170us-gaap_NetIncomeLoss
Net loss attributable to non-controlling interest 138us-gaap_NetIncomeLossAttributableToNoncontrollingInterest 252us-gaap_NetIncomeLossAttributableToNoncontrollingInterest 84us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Net (loss) income attributable to The Medicines Company $ (32,210)us-gaap_ProfitLoss $ 15,512us-gaap_ProfitLoss $ 51,254us-gaap_ProfitLoss
Earnings per common share attributable to The Medicines Company:      
Basic (USD per share) $ (0.50)us-gaap_EarningsPerShareBasic $ 0.27us-gaap_EarningsPerShareBasic $ 0.96us-gaap_EarningsPerShareBasic
Diluted (USD per share) $ (0.50)us-gaap_EarningsPerShareDiluted $ 0.25us-gaap_EarningsPerShareDiluted $ 0.93us-gaap_EarningsPerShareDiluted
Weighted average number of common shares outstanding:      
Basic (shares) 64,473us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 58,096us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 53,545us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
Diluted (shares) 64,473us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 62,652us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 55,346us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding